Rongchang Biotech announced that due to the cumulative decline in A-share prices over 20 consecutive trading days, in order to protect the company's value and shareholders' rights, the company plans to use centralized bidding to repurchase A-shares with a repurchase amount of no less than 30 million yuan, no more than 60 million yuan, and no more than 131 yuan/share. The estimated number of repurchases is 229,000 shares to 458 million shares, accounting for 0.04% to 0.08% of the total share capital. The repurchase period is 3 months from the date of review and approval by the board of directors, and the funding source is own and/or self-funded. The shares repurchased will be sold at an opportunity 12 months after the repurchase results are disclosed, and the portion not sold out within 3 years will be cancelled. The company's controlling shareholders, actual controllers, directors and supervisors, and shareholders holding 5% or more of the shares have no plans to reduce their holdings within the next 6 months.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.